Ascentage Pharma Group International : Towards the breakout of a major resistance level
| Entry price | Target | Stop-loss | Potential |
|---|
|
HK$46.35 |
HK$75 |
HK$35 |
+61.81% |
|---|
Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Ascentage Pharma Group International. The stock's technical chart pattern suggests however that the level will be broken.
Strengths● Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
● Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The stock is in a well-established, long-term rising trend above the technical support level at 33 HKD
● Stock prices approach a strong long-term resistance in weekly data at HKD 47.13.
● The stock is close to a major daily resistance at HKD 46.95, which should be gotten rid of so as to gain new appreciation potential.
● The company has insufficient levels of profitability.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
ASCENTAGE PHARMA GROUP INTERNATIONAL 
